Noncanonical NF-kB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2574-2586

  Yu, Jinpu ^a   Wang, Yue ^a   Yan, Fang ^a,b   Zhang, Peng ^a   Li, Hui ^a   Zhao, Hua ^a   Yan, Cihui ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CELL ENZYME; CUCURBITACIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JSI 124; PROTEIN IDO; PROTEIN P100; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; CUCURBITACIN I; IL6 PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; RELB PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TRITERPENE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ACTIVE TRANSPORT; BONE MARROW CELL; BREAST TUMOR; CELL NUCLEUS; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; PATHOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-6; MYELOID CELLS; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELB; TRITERPENES; UP-REGULATION;

EID: 84907029151     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400833     Document Type: Article

References (51)

1. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
2. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
3. Mougiakakos, D., R. Jitschin, L. von Bahr, I. Poschke, R. Gary, B. Sundberg, A. Gerbitz, P. Ljungman, and K. Le Blanc. 2013. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 27: 377-388.
4. Yu, J.,W. Du, F. Yan, Y.Wang, H. Li, S. Cao,W. Yu, C. Shen, J. Liu, and X. Ren. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190: 3783-3797.
5. Medzhitov, R., E. M. Shevach, G. Trinchieri, A. L. Mellor, D. H. Munn, S. Gordon, P. Libby, G. K. Hansson, K. Shortman, C. Dong, et al. 2011. Highlights of 10 years of immunology in Nature Reviews Immunology. Nat. Rev. Immunol. 11: 693-702.
6. Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189: 1363-1372.
7. Sim, S. H., Y. O. Ahn, J. Yoon, T. M. Kim, S. H. Lee, D. W. Kim, and D. S. Heo. 2012. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of nonsmall cell lung cancer. Cancer Sci. 103: 155-160.
8. Furset, G., Y. Fløisand, and M. Sioud. 2008. Impaired expression of indoleamine 2,3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology 123: 263-271.
9. Wang, Y., B. H. Yang, H. Li, S. Cao, X. B. Ren, and J. P. Yu. 2013. IDO+ DCs and signalling pathways. Curr. Cancer Drug Targets 13: 278-288.
10. Wen, Z., Z. Zhong, and J. E. Darnell, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250.
11. Renard, P., I. Ernest, A. Houbion, M. Art, H. Le Calvez, M. Raes, and J. Remacle. 2001. Development of a sensitive multi-well colorimetric assay for active NFkB. Nucleic Acids Res. 29: E21.
12. Schneider, G., D. Saur, J. T. Siveke, R. Fritsch, F. R. Greten, and R. M. Schmid. 2006. IKKa controls p52/RelB at the skp2 gene promoter to regulate G1-to S-phase progression. EMBO J. 25: 3801-3812.
13. Barré, B., and N. D. Perkins. 2007. A cell cycle regulatory network controlling NF-kB subunit activity and function. EMBO J. 26: 4841-4855.
14. Oh, Y. M., J. K. Kim, Y. Choi, S. Choi, and J. Y. Yoo. 2009. Prediction and experimental validation of novel STAT3 target genes in human cancer cells. PLoS ONE 4: e6911.
15. Wang, B. D., V. Yong-Gonzalez, and A. V. Strunnikov. 2004. Cdc14p/FEAR pathway controls segregation of nucleolus in S. Crevisiae by facilitating condensin targeting to rDNA chromatin in anaphase. Cell Cycle 3: 960-967.
16. Li, H., C. Wang, J. Yu, S. Cao, F. Wei, W. Zhang, Y. Han, and X. B. Ren. 2009. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11: 1076-1083.
17. Wehinger, J., F. Gouilleux, B. Groner, J. Finke, R. Mertelsmann, and R. M. Weber-Nordt. 1996. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 394: 365-370.
18. Matikainen, S., T. Sareneva, T. Ronni, A. Lehtonen, P. J. Koskinen, and I. Julkunen. 1999. Interferon-α activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 93: 1980-1991.
19. Chen, B., L. He, V. H. Savell, J. J. Jenkins, and D. M. Parham. 2000. Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res. 60: 3290-3298.
20. Andersen, P., M. W. Pedersen, A. Woetmann, M. Villingshøj, M. T. Stockhausen, N. Odum, and H. S. Poulsen. 2008. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int. J. Cancer 122: 342-349.
21. Zhang, H., H. Nguyen-Jackson, A. D. Panopoulos, H. S. Li, P. J. Murray, and S. S. Watowich. 2010. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116: 2462-2471.
22. Robinson, C. M., P. T. Hale, and J. M. Carlin. 2005. The role of IFN-γ and TNFα-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J. Interferon Cytokine Res. 25: 20-30.
23. Nakajima, T., S. Kinoshita, T. Sasagawa, K. Sasaki, M. Naruto, T. Kishimoto, and S. Akira. 1993. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA 90: 2207-2211.
24. Blaskovich, M. A., J. Sun, A. Cantor, J. Turkson, R. Jove, and S. M. Sebti. 2003. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63: 1270-1279.
25. Nefedova, Y., S. Nagaraj, A. Rosenbauer, C. Muro-Cacho, S. M. Sebti, and D. I. Gabrilovich. 2005. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65: 9525-9535.
26. Grivennikov, S. I., and M. Karin. 2010. Dangerous liaisons: STAT3 and NF-kB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19.
27. Nadiminty, N., W. Lou, S. O. Lee, X. Lin, D. L. Trump, and A. C. Gao. 2006. Stat3 activation of NF-kB p100 processing involves CBP/p300-mediated acetylation. Proc. Natl. Acad. Sci. USA 103: 7264-7269.
28. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
29. Puccetti, P., and U. Grohmann. 2007. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kB activation. Nat. Rev. Immunol. 7: 817-823.
30. Pine, R. 1997. Convergence of TNFα and IFNγ signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kB promoter element. Nucleic Acids Res. 25: 4346-4354.
31. Ozes, O. N., L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner. 1999. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
32. Ling, L., Z. Cao, and D. V. Goeddel. 1998. NF-kB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA 95: 3792-3797.
33. Sun, S. C. 2012. The noncanonical NF-kB pathway. Immunol. Rev. 246: 125-140.
34. Sun, S. C. 2011. Non-canonical NF-kB signaling pathway. Cell Res. 21: 71-85.
35. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
36. Uyttenhove, C., L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B. J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9: 1269-1274.
37. Babcock, T. A., and J. M. Carlin. 2000. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor a in interferon-treated epithelial cells. Cytokine 12: 588-594.
38. Yang, L., J. Huang, X. Ren, A. E. Gorska, A. Chytil, M. Aakre, D. P. Carbone, L. M. Matrisian, A. Richmond, P. C. Lin, and H. L. Moses. 2008. Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
39. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179: 977-983.
40. Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, P. Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69: 2514-2522.
41. Lechner, M. G., C. Megiel, S. M. Russell, B. Bingham, N. Arger, T. Woo, and A. L. Epstein. 2011. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 9: 90.
42. Lechner, M. G., D. J. Liebertz, and A. L. Epstein. 2010. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185: 2273-2284.
43. DiDonato, J. A., F. Mercurio, and M. Karin. 2012. NF-kB and the link between inflammation and cancer. Immunol. Rev. 246: 379-400.
44. Yamaguchi, N., T. Ito, S. Azuma, E. Ito, R. Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J. Imai, S. Watanabe, et al. 2009. Constitutive activation of nuclear factor-kB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 100: 1668-1674.
45. Ling, X., and R. B. Arlinghaus. 2005. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65: 2532-2536.
46. Smith, C., M. Y. Chang, K. H. Parker, D. W. Beury, J. B. DuHadaway, H. E. Flick, J. Boulden, E. Sutanto-Ward, A. P. Soler, L. D. Laury-Kleintop, et al. 2012. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2: 722-735.
47. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
48. Kim, H., L. Chen, G. Lim, B. Sung, S. Wang, M. F. McCabe, G. Rusanescu, L. Yang, Y. Tian, and J. Mao. 2012. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 122: 2940-2954.
49. Orabona, C., M. L. Belladonna, C. Vacca, R. Bianchi, F. Fallarino, C. Volpi, S. Gizzi, M. C. Fioretti, U. Grohmann, and P. Puccetti. 2005. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. 174: 6582-6586.
50. Orabona, C., U. Grohmann, M. L. Belladonna, F. Fallarino, C. Vacca, R. Bianchi, S. Bozza, C. Volpi, B. L. Salomon, M. C. Fioretti, et al. 2004. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5: 1134-1142.
51. Isomoto, H. 2009. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/ STAT3 signaling in cholangio-carcinoma due to SOCS3 epigenetic silencing. Digestion 79(Suppl. 1): 2-8.